利博西林用於製備治療罹患磷酸二酯酶4介導疾病的患者的醫藥組合物及用途PHARMACEUTICAL COMPOSITION AND USE FOR APPLYING RIBOCICLIB IN PHOSPHODIESTERASE 4-MEDIATED DISEASE TREATMENT OF PATIENT

Tsong-Long Hwang; PO-JEN CHEN

利博西林用於製備治療罹患磷酸二酯酶4介導疾病的患者的醫藥組合物及用途PHARMACEUTICAL COMPOSITION AND USE FOR APPLYING RIBOCICLIB IN PHOSPHODIESTERASE 4-MEDIATED DISEASE TREATMENT OF PATIENT

Translated title of the contribution: PHARMACEUTICAL COMPOSITION AND USE FOR APPLYING RIBOCICLIB IN PHOSPHODIESTERASE 4-MEDIATED DISEASE TREATMENT OF PATIENT

Tsong-Long Hwang (Inventor), PO-JEN CHEN (Inventor)

School of Traditional Chinese Medicine

Research output: Patent

Abstract

The disclosure provides a pharmaceutical composition for phosphodiesterase 4-mediated disease treatment of patient and inhibition of phosphodiesterase 4 activity. The pharmaceutical composition includes an effective amount of Ribociclib and a pharmaceutically acceptable carrier. The disclosure further provides a use of the Ribociclib for manufacturing the pharmaceutical composition for phosphodiesterase 4-mediated disease treatment of patient. The application of the pharmaceutical composition and the use of the present invention are advantageous for inhibiting of phosphodiesterase 4 activity and thus treating a phosphodiesterase 4-mediated disease.

Translated title of the contribution	PHARMACEUTICAL COMPOSITION AND USE FOR APPLYING RIBOCICLIB IN PHOSPHODIESTERASE 4-MEDIATED DISEASE TREATMENT OF PATIENT
Original language	Chinese (Traditional)
IPC	A61K 31/519(2006.01); A61P 37/00(2006.01); C07D 471/04(2006.01)
State	Published - 01 01 2021

Bibliographical note

公開公告號: 2.02100158E8
Announcement ID: 2.02100158E8

Cite this

@misc{5b7111f25f8b4e60ace184e45584994c,

title = "利博西林用於製備治療罹患磷酸二酯酶4介導疾病的患者的醫藥組合物及用途PHARMACEUTICAL COMPOSITION AND USE FOR APPLYING RIBOCICLIB IN PHOSPHODIESTERASE 4-MEDIATED DISEASE TREATMENT OF PATIENT",

abstract = "本發明揭露一種用於治療罹患磷酸二酯酶4介導疾病的患者以及用於抑制磷酸二酯酶4的活性的醫藥組合物，其包括有效劑量的利博西林（Ribociclib）以及醫藥上可接受的載體。本發明另揭露一種利博西林用於製備治療罹患磷酸二酯酶4介導疾病的患者的醫藥組合物之用途。利用本發明之用途及醫藥組合物，可有效的抑制磷酸二酯酶4的活性，並可治療磷酸二酯酶4介導疾病。",

author = "Tsong-Long Hwang and PO-JEN CHEN",

note = "A61K 31/519(2006.01); A61P 37/00(2006.01); C07D 471/04(2006.01)",

year = "2021",

month = jan,

day = "1",

language = "繁體中文",

type = "Patent",

}

TY - PAT

T1 - 利博西林用於製備治療罹患磷酸二酯酶4介導疾病的患者的醫藥組合物及用途PHARMACEUTICAL COMPOSITION AND USE FOR APPLYING RIBOCICLIB IN PHOSPHODIESTERASE 4-MEDIATED DISEASE TREATMENT OF PATIENT

AU - Hwang, Tsong-Long

AU - CHEN, PO-JEN

N1 - 公開公告號: 2.02100158E8 Announcement ID: 2.02100158E8

PY - 2021/1/1

Y1 - 2021/1/1

N2 - 本發明揭露一種用於治療罹患磷酸二酯酶4介導疾病的患者以及用於抑制磷酸二酯酶4的活性的醫藥組合物，其包括有效劑量的利博西林（Ribociclib）以及醫藥上可接受的載體。本發明另揭露一種利博西林用於製備治療罹患磷酸二酯酶4介導疾病的患者的醫藥組合物之用途。利用本發明之用途及醫藥組合物，可有效的抑制磷酸二酯酶4的活性，並可治療磷酸二酯酶4介導疾病。

AB - 本發明揭露一種用於治療罹患磷酸二酯酶4介導疾病的患者以及用於抑制磷酸二酯酶4的活性的醫藥組合物，其包括有效劑量的利博西林（Ribociclib）以及醫藥上可接受的載體。本發明另揭露一種利博西林用於製備治療罹患磷酸二酯酶4介導疾病的患者的醫藥組合物之用途。利用本發明之用途及醫藥組合物，可有效的抑制磷酸二酯酶4的活性，並可治療磷酸二酯酶4介導疾病。

M3 - 專利

ER -

利博西林用於製備治療罹患磷酸二酯酶4介導疾病的患者的醫藥組合物及用途PHARMACEUTICAL COMPOSITION AND USE FOR APPLYING RIBOCICLIB IN PHOSPHODIESTERASE 4-MEDIATED DISEASE TREATMENT OF PATIENT

Abstract

Bibliographical note

Fingerprint

Cite this